ATA26687A - Verfahren zur herstellung eines melanom-assoziierten antigens - Google Patents

Verfahren zur herstellung eines melanom-assoziierten antigens

Info

Publication number
ATA26687A
ATA26687A AT0026687A AT26687A ATA26687A AT A26687 A ATA26687 A AT A26687A AT 0026687 A AT0026687 A AT 0026687A AT 26687 A AT26687 A AT 26687A AT A26687 A ATA26687 A AT A26687A
Authority
AT
Austria
Prior art keywords
antigent
melanoma
producing
associated antigent
Prior art date
Application number
AT0026687A
Other languages
English (en)
Other versions
AT396938B (de
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of ATA26687A publication Critical patent/ATA26687A/de
Application granted granted Critical
Publication of AT396938B publication Critical patent/AT396938B/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
AT0026687A 1986-02-07 1987-02-09 Verfahren zur herstellung eines melanom-assoziierten antigens AT396938B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82731386A 1986-02-07 1986-02-07

Publications (2)

Publication Number Publication Date
ATA26687A true ATA26687A (de) 1993-05-15
AT396938B AT396938B (de) 1993-12-27

Family

ID=25248895

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0026687A AT396938B (de) 1986-02-07 1987-02-09 Verfahren zur herstellung eines melanom-assoziierten antigens

Country Status (8)

Country Link
US (1) US5262177A (de)
KR (1) KR870008030A (de)
AT (1) AT396938B (de)
AU (1) AU606046B2 (de)
FR (1) FR2601370B1 (de)
IL (1) IL81481A0 (de)
LU (1) LU86765A1 (de)
ZA (1) ZA87880B (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE20000918A1 (en) * 1990-03-22 2001-05-30 Sloan Kettering Inst Cancer GP75 As a Tumor Vaccine for Melanoma
CA2113990A1 (en) * 1991-07-26 1993-02-18 Frederick L. Moolten Cancer therapy utilizing malignant cells
US5462871A (en) * 1992-08-31 1995-10-31 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode MAGE derived nonapeptides
AU686660B2 (en) * 1993-08-11 1998-02-12 Jenner Technologies Prostatic cancer vaccine
ES2224113T5 (es) * 1994-02-16 2009-05-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Polipeptido antigenico asociado al melanoma, epitopos del mismo y vacunas contra melanoma.
WO1995029193A2 (en) 1994-04-22 1995-11-02 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Melanoma antigens
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US7662396B2 (en) * 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US7820180B2 (en) * 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US8114414B2 (en) * 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US8791237B2 (en) * 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US20070264279A1 (en) * 1994-11-08 2007-11-15 Claudia Gravekamp Compositions and methods comprising a MAGE-b antigen
US5843648A (en) * 1995-01-10 1998-12-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
EP0914607A2 (de) * 1995-09-15 1999-05-12 Samir Chachoua Verfahren zur erkennung und therapeutische verwendung von krankheitsassoziierten organismen, elementen und kräften
US7501501B2 (en) * 1995-09-26 2009-03-10 The United States Of America As Represented By The Secretary Department Of Health And Human Services MHC-Class II restricted melanoma antigens and their use in therapeutic methods
US6951917B1 (en) 1995-09-26 2005-10-04 The United States Of America As Represented By The Department Of Health And Human Services MHC-class II restricted melanoma antigens and their use in therapeutic methods
US20040156861A1 (en) * 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma
US6328969B1 (en) * 1996-12-10 2001-12-11 Sloan-Kettering Institute For Cancer Research Method and compositions for stimulation of an immune response to a differentiation antigen stimulated by an altered differentiation antigen
US7556805B2 (en) * 1996-12-10 2009-07-07 Sloan-Kettering Inststute for Cancer Research and The Animal Medical Center Compositions for treatment of melanoma and method of using same
US8021666B2 (en) * 1997-02-18 2011-09-20 Sloan-Kettering Institute For Cancer Research Method and compositions for stimulation of an immune response to CD20 using a xenogeneic CD20 antigen
US20020164318A1 (en) * 1997-02-18 2002-11-07 Houghton Alan N. Cell lines and vectors for stimulation of an immune response to a differentiation antigen stimulated by an altered antigen
US20100068262A1 (en) * 1997-02-18 2010-03-18 Sloan-Kettering Institute For Cancer Research Method and Compositions for Stimulation of an Immune Response to PSMA using a Xenogeneic PSMA Antigen
US20100068263A1 (en) * 1997-02-18 2010-03-18 Sloan-Kettering Institute For Cancer Research Method and Compositions for Stimulation of an Immune Response to TRP2 using a Xenogeneic TRP2 Antigen
DE19821925A1 (de) * 1998-05-15 1999-11-18 Roehnisch Tim Verfahren zur Herstellung einer Zusammensetzung zur Induktion einer tumorspezifischen Immunantwort, sowie Verwendung der Zusammensetzung zur Behandlung von Neoplasien
WO2000061184A2 (en) 1999-04-08 2000-10-19 Glenn Gregory M Dry formulation for transcutaneous immunization
AU2001234616A1 (en) * 2000-01-31 2001-08-07 Vic Jira Vaccine composition, process and methods
EP1285272A2 (de) * 2000-02-08 2003-02-26 University of British Columbia Zusammensetzungen und verfahren zum screenen von therapeutischen agenzien
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
JP2004500405A (ja) * 2000-03-29 2004-01-08 ザ　トラスティーズ　オブ　ザ　ユニバーシティー　オブ　ペンシルヴァニア 抗原の免疫原性を増強するための組成物および方法
US6855320B2 (en) * 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US7700344B2 (en) * 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US7419957B2 (en) * 2001-08-22 2008-09-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides of melanoma antigen and their use in diagnostic, prophylactic and therapeutic methods
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
US20070031440A1 (en) * 2001-08-30 2007-02-08 Prior Christopher P Modified transferin-antibody fusion proteins
CN1628126A (zh) * 2001-08-30 2005-06-15 比奥雷克西斯药物公司 经修饰的运铁蛋白融合蛋白
CN102268094A (zh) * 2002-08-30 2011-12-07 比奥雷克西斯药物公司 被修饰的转铁蛋白抗体的融合蛋白
US20060105387A1 (en) * 2002-08-30 2006-05-18 Prior Christopher P Transferrin fusion proteins libraries
US20070060512A1 (en) * 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
US7379700B2 (en) * 2003-05-06 2008-05-27 Canon Kabushiki Kaisha Image reading apparatus with rotatable internal and external guides
US8207314B2 (en) * 2003-05-16 2012-06-26 Sanofi Pasteur Limited Tumor antigens for prevention and/or treatment of cancer
JP2007512001A (ja) * 2003-08-28 2007-05-17 バイオレクシス ファーマシューティカル コーポレイション Ｅｐｏミメティックペプチドおよび融合タンパク質
US20060205037A1 (en) * 2003-08-28 2006-09-14 Homayoun Sadeghi Modified transferrin fusion proteins
EP2258441A3 (de) 2005-09-02 2011-09-21 Intercell USA, Inc. Vorrichtungen für die transkutane Abgabe von Vakzinen und transdermale Abgabe von Arzneimitteln
DK2046826T3 (da) * 2006-07-24 2011-10-24 Biorexis Pharmaceutical Corp Exendin-fusionsproteiner
EP2056849A4 (de) * 2006-08-04 2010-09-08 Univ Pennsylvania Verfahren und zusammensetzungen zur behandlung von ige-vermittelten erkrankungen
US8241636B2 (en) * 2006-08-15 2012-08-14 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
US8268326B2 (en) * 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
JP5757863B2 (ja) 2008-05-19 2015-08-05 アドバクシス インコーポレイテッド 異種抗原のための二重送達システム
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US20090005320A1 (en) * 2008-09-02 2009-01-01 Bruce Kneller Compositions comprising amino acid bicarbonate and methods of use thereof
US8778329B2 (en) 2009-03-04 2014-07-15 The Trustees Of The University Of Pennsylvania Compositions comprising angiogenic factors and methods of use thereof
CN102573883A (zh) 2009-06-12 2012-07-11 疫苗技术公司 用于促进细胞-介导的免疫应答的方法和组合物
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
CN107412756A (zh) 2010-10-01 2017-12-01 宾夕法尼亚大学理事会 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
BR112014022662A2 (pt) 2012-03-12 2017-10-03 Advaxis Inc Inibição da função de célula supressora seguindo tratamento de vacina de listeria
WO2014044690A1 (en) 2012-09-18 2014-03-27 Valneva Austria Gmbh Improved vaccines

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4719177A (en) * 1981-04-20 1988-01-12 Massachusetts Institute Of Technology Production of complementary DNA representing RNA viral sequences by recombinant DNA methods and uses therefor
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus

Also Published As

Publication number Publication date
KR870008030A (ko) 1987-09-23
FR2601370B1 (fr) 1990-06-01
FR2601370A1 (fr) 1988-01-15
IL81481A0 (en) 1987-09-16
AT396938B (de) 1993-12-27
US5262177A (en) 1993-11-16
LU86765A1 (fr) 1987-09-15
AU606046B2 (en) 1991-01-31
AU6862087A (en) 1987-08-13
ZA87880B (en) 1987-09-30

Similar Documents

Publication Publication Date Title
DE3881077D1 (de) Verfahren zur herstellung eines diamantfilms.
AT399655B (de) Verfahren zur herstellung einer multivalenten pneumokokkenvakzine
DE3782979D1 (de) Verfahren zur herstellung eines verglasten produkts.
DE3774944D1 (de) Verfahren zur herstellung eines geformten feuerfesten faserproduktes.
AT369990B (de) Verfahren zur herstellung eines gewebeklebstoffes
DE3687502D1 (de) Verfahren zur herstellung eines wasserundurchlaessigen stoffes.
ATA157388A (de) Verfahren zur herstellung eines dekorationsspiegels
AT399634B (de) Verfahren zur herstellung einer süssware
DE3776240D1 (de) Verfahren zur herstellung eines ferritfilmes.
DE3868128D1 (de) Verfahren zur herstellung eines supraleitenden gegenstandes.
DE3785369D1 (de) Verfahren zur herstellung eines farbbildes.
DE3883279D1 (de) Verfahren zur herstellung eines nassrasierers.
DE3671355D1 (de) Verfahren zur herstellung eines gewuerzes.
DE69024817D1 (de) Verfahren zur herstellung eines punktartig teilweise bedeckten elementes
AT385653B (de) Verfahren zur herstellung eines zahnputzmittels
DE3583818D1 (de) Verfahren zur herstellung eines cyclischen alkohols.
DE3687954D1 (de) Verfahren zur herstellung eines tetraalkoxysilans.
DE3680887D1 (de) Verfahren zur herstellung eines farbbildes.
DE3778069D1 (de) Verfahren zur herstellung eines ringlasers.
ATA233086A (de) Verfahren zur herstellung neuer peptidantibiotika
DE3865507D1 (de) Verfahren zur herstellung eines rasierers.
DE3778922D1 (de) Verfahren zur herstellung eines farbbildes.
DE3672334D1 (de) Verfahren zur herstellung eines kommutators.
DE3783690D1 (de) Verfahren zur herstellung eines kohlensaeureesters.
ATA159188A (de) Verfahren zur herstellung eines kupferspiegels

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties
ELJ Ceased due to non-payment of the annual fee